A quantitative and qualitative evaluation of LISA, a decision support system for chemotherapy dosing in childhood acute lymphoblastic leukaemia.
OBJECTIVE
To assess the acceptability to clinicians of a web-based decision support system designed to assist with dosage adjustments during maintenance therapy for childhood Acute Lymphoblastic Leukaemia (ALL), and to evaluate the potential impact of the system on decision-making and dosage calculations.


METHODS
Balanced-block crossover experiment with simulated cases; questionnaire study and semi-structured interviews.


METHODS
36 clinicians with differing experience in the management of ALL.


METHODS
Subjects were asked to decide on appropriate levels of chemotherapy dosing for 8 simulated cases, 4 using the LISA decision support system, 4 using conventional paper-based records and guidance.


METHODS
Number of protocol-consistent dosage decisions made; time taken to manage each case; accuracy of dosage calculations; subjects' opinions as to whether or not they would use the system in practice. ADDITIONAL OUTCOME MEASURES: Functions subjects would like to see in an idealised system; subjects' satisfaction with the implementation of the functions provided by LISA; qualitative data on issues subjects felt would impact upon the successful deployment of the system.
Bury
Jonathan
J
Division of Genomic Medicine, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK. j.p.bury@sheffield.ac.uk
Hurt
Chris
C
Roy
Anindita
A
Bradburn
Mike
M
Cross
Simon
S
Fox
John
J
Saha
Vaskar
V
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001292:Attitude to Computers; D018592:Cross-Over Studies; D020000:Decision Support Systems, Clinical; D004360:Drug Therapy, Computer-Assisted; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents